Advisory Services Network LLC Buys 13,634 Shares of Bristol-Myers Squibb (NYSE:BMY)

Advisory Services Network LLC boosted its holdings in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 15.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 101,250 shares of the biopharmaceutical company's stock after purchasing an additional 13,634 shares during the quarter. Advisory Services Network LLC's holdings in Bristol-Myers Squibb were worth $5,727,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Fairway Wealth LLC bought a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth about $28,000. Comprehensive Financial Planning Inc. PA bought a new stake in Bristol-Myers Squibb during the 4th quarter worth approximately $34,000. Westend Capital Management LLC purchased a new stake in shares of Bristol-Myers Squibb in the fourth quarter worth approximately $38,000. Tacita Capital Inc bought a new position in shares of Bristol-Myers Squibb in the fourth quarter valued at approximately $39,000. Finally, M Holdings Securities Inc. purchased a new position in shares of Bristol-Myers Squibb during the fourth quarter valued at approximately $39,000. Institutional investors own 76.41% of the company's stock.

Insiders Place Their Bets

In other Bristol-Myers Squibb news, EVP Samit Hirawat bought 1,823 shares of the firm's stock in a transaction on Friday, February 14th. The shares were acquired at an average cost of $54.84 per share, for a total transaction of $99,973.32. Following the purchase, the executive vice president now directly owns 63,932 shares of the company's stock, valued at $3,506,030.88. The trade was a 2.94 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.09% of the company's stock.

Remove Ads

Bristol-Myers Squibb Stock Performance

Bristol-Myers Squibb stock traded up $0.36 during mid-day trading on Monday, reaching $51.07. The company's stock had a trading volume of 4,879,542 shares, compared to its average volume of 12,087,845. The firm's fifty day moving average price is $57.71 and its two-hundred day moving average price is $56.78. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $63.33. The company has a market capitalization of $103.92 billion, a P/E ratio of -11.55, a PEG ratio of 2.07 and a beta of 0.41.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. Sell-side analysts predict that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Friday, April 4th will be paid a dividend of $0.62 per share. The ex-dividend date of this dividend is Friday, April 4th. This represents a $2.48 annualized dividend and a yield of 4.86%. Bristol-Myers Squibb's dividend payout ratio is currently -56.11%.

Analyst Ratings Changes

BMY has been the topic of a number of analyst reports. Truist Financial lifted their price objective on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. Citigroup increased their price objective on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a "neutral" rating in a research note on Tuesday, January 28th. UBS Group cut their target price on Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research note on Friday. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $55.00 price target (down from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. Finally, Wells Fargo & Company boosted their price objective on Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a research report on Friday, February 7th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating, four have given a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $57.67.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.